Study S001239

Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01588418
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 15
Start: 2010-07
Primary completion: 2015-07
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Impaired Glucose Tolerance (IGT); Diabetes
Interventions: DRUG:Exenatide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism [120 minutes after exenatide or placebo injection]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020730	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Gastaldelli A, Hepatology (Baltimore, Md.)	2016	Other	PMID 27639082 DOI	cites ClinicalTrials.gov:NCT01588418; registry reference RESULT:27639082
R0016839	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Daniele G, Diabetes	2015	Randomized trial	PMID 26116695 DOI	cites ClinicalTrials.gov:NCT01588418; registry reference RESULT:26116695
R0035757	Exenatide Increases Glucose Uptake in Brain Areas Involved in Glucose Homeostasis and Food Intake Daniel Bittner, MD Conference Express	2014	Other trial	DOI	cites ClinicalTrials.gov:NCT01588418